Huron price target raised to $180 from $165 at Truist

Truist raised the firm’s price target on Huron (HURN) to $180 from $165 and keeps a Buy rating on the shares after its Q4 earnings beat. Huron’s core Healthcare and Higher Education markets are likely to grow more quickly than previously thought due to changes in federal spending, the analyst tells investors in a research note. A 15% cap on overhead charges allowed for NIH grants to academic medical centers could prompt larger enterprise projects at universities, while pending federal healthcare spending cuts could spur favorable demand for performance improvement services at hospitals through 2027, the firm adds.